Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

    Virtual Booth

    Contact Supplier

    Coral

    Virtual Booth

    Contact Supplier

    ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

    Virtual Booth

    Contact Supplier

    Menu

    Ravulizumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 3Alexion Pharma Canada, AstraZeneca Rare Disease

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Alexion Pharma Canada, Astra...

    RAVULIZUMAB
    arrow
    Formnext Forum
    Not Confirmed

    Alexion Pharma Canada, AstraZeneca Rare Di...

    Country
    arrow
    Formnext Forum
    Not Confirmed

    Patent Expiration Date : 2035-03-06

    Date Granted : 2022-11-08

    RAVULIZUMAB

    Brand Name : ULTOMIRIS

    Patent Number : 2942165

    Filing Date : 2015-03-06

    Strength per Unit : 10mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : INTRAVENOUS

    Patent Expiration Date : 2035-03-06

    Date Granted : 2022-11-08

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Alexion Pharma Canada, Astra...

    RAVULIZUMAB
    arrow
    Formnext Forum
    Not Confirmed

    Alexion Pharma Canada, AstraZeneca Rare Di...

    Country
    arrow
    Formnext Forum
    Not Confirmed

    Patent Expiration Date : 2035-03-06

    Date Granted : 2022-11-08

    RAVULIZUMAB

    Brand Name : ULTOMIRIS

    Patent Number : 2942165

    Filing Date : 2015-03-06

    Strength per Unit : 100 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : INTRAVENOUS

    Patent Expiration Date : 2035-03-06

    Date Granted : 2022-11-08

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Alexion Pharma Canada, Astra...

    RAVULIZUMAB
    arrow
    Formnext Forum
    Not Confirmed

    Alexion Pharma Canada, AstraZeneca Rare Di...

    Country
    arrow
    Formnext Forum
    Not Confirmed

    Patent Expiration Date : 2035-03-06

    Date Granted : 2022-11-08

    RAVULIZUMAB

    Brand Name : ULTOMIRIS

    Patent Number : 2942165

    Filing Date : 2015-03-06

    Strength per Unit : 100 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : INTRAVENOUS

    Patent Expiration Date : 2035-03-06

    Date Granted : 2022-11-08

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF